Blueprint & Bottle™The Study
What we're reading.
New ingredients, emerging research, and what we're exploring at Blueprint & Bottle.
This is the part of the work that never appears on a label.
Before a formula exists, there are months of reading — ingredient files, supplier conversations, papers, and the occasional dead end. The Study is where that gets written down. Not a trend report, and not a promise about what a product will do. A record of what caught our attention, what the evidence actually supports, and what still has to be tested before it goes near a practice's shelf.
Every note keeps three things apart on purpose: what interests us, what the evidence supports, and what still needs testing. Interest is not proof, and we'd rather say so in the note than let it slide.
Fig. 01
Delivery over lists
An active is easy to name. Getting it through the skin and keeping it stable there is the work.
What interests us
Encapsulation, lipid carriers, and how a formula moves an active rather than simply containing it.
What the evidence supports
Penetration and vehicle design have a long published history, and it keeps getting more specific.
What still needs testing
Whether a carrier that performs on its own still performs inside a complete formula, used daily, for months.
Fig. 02
Stability is the quiet half
A formula that changes in the bottle hasn't been finished yet.
What interests us
Oxidation, light and heat, and the stabilizer systems that hold an active where it sat on day one.
What the evidence supports
Degradation pathways for common actives are well documented. The difficulty is holding a system still without dulling it.
What still needs testing
Shelf life in the pack we actually intend to ship, at the temperatures a practice's bathroom really reaches.
Fig. 03
The scalp is skin
The rigor applied to the face belongs a few centimeters higher.
What interests us
Barrier, microbiome and sebum — and what changes when the scalp is treated as skin rather than as a root problem.
What the evidence supports
Scalp conditions are well studied in their own right; the crossover into cosmetic formulation is newer and less standardized.
What still needs testing
Whether a scalp-first formula can stay pleasant in use — weight, scent, finish — while doing the work.
We are interested in what is new. We are more interested in what holds up.
Notes are written for us and for the practices we work with. They are not medical advice, and nothing here is a claim about a finished product.
Notes from the Study
One email when there's something worth reading. Nothing else, and nothing sold on.
Your address is used for these notes only. We don't promise a schedule — when a note is worth writing, we send it.
The Study
Reading this with us?
If you're thinking about a line of your own, the conversation starts in the same place.